Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer
In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer. Dr Abramson says that they are looking at new mutations within the subgroups, specificallyPI3 kinase mutations, as targets for estrogen receptor positive breast cancer. For HER-2 positive breast cancer there are many new therapies such as, ado-trastuzumab emtansine, pertuzumab, trastuzumab and more. "That's where I really think breast cancer is headed, said Dr Abramson. "We are figuring out how we can target specific subtypes in a better way."
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
The FDA today granted accelerated approval to olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, for treatment of advanced ovarian cancer in women with defected BRCA genes, along with a companion diagnostic test that marked the agency’s first approval of a laboratory developed test (LDT) under a premarket approval application.
In this segment, the panelists analyze current programs that aim to educate and guide key stakeholders through the facets of cancer care and conclude that collaboration can help control costs and drive quality.
All medical illnesses have issues with nonadherence and part of the reason is because the American health system doesn’t provide the right education, support, and close follow-up needed to get the right medicine to the right person, Wayne Katon, MD, said.
Although not often included in pathways due to their recent introduction into clinical practice, immunotherapies are playing important roles in the treatment of many types of cancer. In this segment, the panelists discuss the use of immunotherapies and how to evaluate safety in the context of pathways.
Providers consider many factors when selecting a branded oncology drug over a generic, comment Drs Michael Kolodziej and Ira Klein. The panel continues their discussion addressing concerns over toxicity, safety, and cost.
In this segment, Christopher Sweeney, MBBS, discusses the results of the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED). Dr Sweeney also discusses how the results of CHAARTED have impacted the treatment of patients with prostate cancer and influenced research on combination therapy.
Christopher Sweeney, MBBS, describes 2 patient cases that demonstrate the variability in disease course among patients with castration-resistant prostate cancer and explains how variability affects treatment decisions. Dr Sweeney also discusses the emergence of a promising biomarker to help determine whether or not a patient would respond to hormonal therapy.